Select Medical Holdings (SEM) EBITDA (2018 - 2026)

Select Medical Holdings has disclosed EBITDA across 9 years of filings, most recently posting $98.4 million for Q1 2026.

• In Q1 2026, EBITDA fell 12.71% year-over-year to $98.4 million; the TTM figure through Mar 2026 stood at $321.8 million (up 22.56% YoY), while the FY2025 annual figure was $474.7 million, up 15.94% from the prior year.
• EBITDA advanced to $98.4 million in Q1 2026, from $63.9 million in the prior quarter.
• Over the last five years, EBITDA for SEM reached as high as $159.2 million in Q2 2023 and fell as low as -$173.4 million in Q4 2023.
• The 5-year median for EBITDA is $91.5 million (2022), against an average of $65.6 million.
• Annual changes were most pronounced in 2022 — EBITDA tumbled 321.39% — and 2025, when it surged 203.14%.
• A 5-year view of EBITDA shows it stood at -$171.7 million in 2022, then declined by 1.0% to -$173.4 million in 2023, then jumped by 112.16% to $21.1 million in 2024, then surged by 203.14% to $63.9 million in 2025, then jumped by 53.93% to $98.4 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $98.4 million, $63.9 million, and $73.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.